In a murine glioblastoma setting, administration of the bevacizumab analog B20.4.1.1 was associated with heightened TNF-α release by GAMs and increased endothelial activation—findings that may underlie the observed inefficacy of anti-angiogenic strategies in glioblastoma treatment (63, 64). This evidence concerns the gene TNF and glioblastoma.